Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Afamitresgene autoleucel (HCPCS Q205700) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 1, 2026 , from http://ppman.hank.ai/transparency/procedure/Q205700/by-state?code_type=HCPCS
“Afamitresgene autoleucel (HCPCS Q205700) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/Q205700/by-state?code_type=HCPCS. Accessed
July 1, 2026 .
“Afamitresgene autoleucel (HCPCS Q205700) by State,” HANK Price Transparency ,
accessed July 1, 2026 ,
http://ppman.hank.ai/transparency/procedure/Q205700/by-state?code_type=HCPCS.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
HCPCS · across United States
Q205700 — Afamitresgene Autoleucel
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$1,032,631
National median
$1,032,631 – $2,204,802
IQR (p25 – p75)
4
hospitals filing
2
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for Q205700 (HCPCS), with interquartile range
State Median p25 p75
NV $2,595,525 $2,595,525 $2,595,525
NY $1,032,631 $1,032,631 $1,032,631